Zsa Zsa Weerts

Chapter 6 136 irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007;39:530-536. 24. Liu J, Chen G, Yeh H, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32: 765-768. 25. Schellekens RC, Stellaard F, Olsder GG, et al. Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers. J Control Release 2010; 146:334-340. 26. Maurer JM, Schellekens RC, van Rieke HM, et al. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. J Control Release 2013;172:618-624. 27. Schellekens RC, Stellaard F, Mitrovic D, et al. Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. J Control Release 2008;132:91-98. 28. Schellekens RC, Stuurman FE, van der Weert FH, et al. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products. Eur J Pharm Sci 2007;30:15-20. 29. Maurer MJ, Schellekens RC, Wutzke KD, et al. Isotope-labelled urea to test colon drug delivery devices in vivo: principles, calculations and interpretations. Isotopes Environ Health Stud 2013;49:473-491. 30. European Medicines Agency (EMA) Committee for Medicial Products for Human use (CHMP). Guideline on the investigation of bioequivalence, 2010. 31. U.S.Department of Health and Human Services Food and Drug Administration Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations, 2002. 32. European Pharmacopoeia Commission. European Pharmacopoeia (Ph.Eur.) Monograph Peppermint oil 2014. 33. Schellekens R, Stellaard F, Olsder G, et al. Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers. J Control Release 2010;146:334-340. 34. Mascher H, Kikuta C, Schiel H. Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil. Arzneimittel-Forschung 2001;51: 465-469. 35. Hiki N, Kaminishi M, Hasunuma T, et al. A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of L-Menthol in Upper Gastrointestinal Endoscopy. Clin Pharmacol Ther 2011;90: 221-228. 36. Gelal A, Jacob P 3rd, Yu L, et al. Disposition kinetics and effects of menthol. Clin Pharmacol Ther 1999;66:128-135. 37. Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996;39:299-305. 38. Abuhelwa AY, Foster DJ, Upton RN. A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time. AAPS J 2016;18:1322-1333. 39. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103-141. 40. Tracy TS, Chaudhry AS, Prasad B, et al. Interindividual Variability in Cytochrome P450- Mediated Drug Metabolism. Drug Metab Dispos 2016;44:343-351. 41. Alam MS, Roy PK, Miah AR, et al. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study. Mymensingh Med J 2013;22:27-30. 42. Bautista D, Siemens J, Glazer J, et al. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 2007;448:204-208. 43. Keszthelyi D, Troost FJ, Jonkers DM, et al. Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation? Eur J Pain 2013;17:1299- 1306. 44. Ramachandran R, Hyun E, Zhao L, et al. TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proc Natl Acad Sci U S A 2013;110:7476-7481. 45. Karashima Y, Damann N, Prenen J, et al. Bimodal action of menthol on the transient